AKT1 and breast cancer: The transmembrane protein-45A (TMEM45A) induces glycolysis and EMT program by activating AKT/mTOR signaling pathway, therefore the siRNA targeting TMEM45A can reverse the above pathway and improve the sensitivity of breast cancer to palbocilib (221).